Eli Lilly shares rise after EU panel backs expanded use of Jaypirca
Eli Lilly shares rise after EU panel backs expanded use of Jaypirca Proactive uses images sourced from Shutterstock…
Most of Wall Street rises, but sinking AI stocks send it lower for the week
NEW YORK (AP) — Most of the U.S. stock market rose Friday after oil prices eased back to…
J&J CEO sends a clear message on the obesity drug boom
Johnson & Johnson (JNJ) just told Wall Street it will sit out the most lucrative drug race of…
Mystery Patient, Age 79, Got Special Access to Weight Drug
One of the more intriguing stories of the day comes from STAT News, which reports that a…
Eli Lilly ends 340B drug discounts to some hospitals over missing claims data
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Scott Galloway says GLP-1 drugs are a ‘silver bullet’ for America’s woes, if we’re not ‘stupid enough’ to get in the way
On June 12, SpaceX (NASDAQ: SPCX) had the biggest IPO on record, making $75 billion (1) — but…
Warning issued over counterfeit weight-loss drugs labelled as retatrutide
Senior doctors from a hospital in Melbourne’s north are warning people against taking drugs being labelled as experimental…
Can Wegovy Pill’s Europe Push Help NVO Offset Mounting Pressures?
Last week, Novo Nordisk NVO secured a key regulatory win with the U.K. approval of the Wegovy pill…
Do GLP-1 pills work as well as injections? Here’s what studies show about weight loss, side effects
(NEXSTAR) – GLP-1 drugs, which have grown incredibly popular in recent years for their ability to help people…
Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it
On Thursday morning in New York City, Dr. Shiv Rao stood before a room of health system executives…
New Weight Loss Drug Could Beat Ozempic’s Results—When It’s Coming
A new experimental weight loss drug from Eli Lilly could produce greater weight loss results than popular medications…
Novo’s Wegovy Pill Isn’t Just Beating Expectations — It’s Obliterating Them. Is the Beaten-Down Stock a Buy Now?
The pharmaceutical industry is highly competitive and driven by innovation. Those two facts couldn’t be on any clearer…